As a result of the firm's financial results, Castle Bio raised its full-year 2025 revenue guidance to between $327 and $335 million from a range of $310 to $320 million.

(Lancet Gastroenterology & Hepatology) Upon pH-monitoring of asymptomatic Barrett's esophagus patients on proton pump ...

Peer-Reviewed Study Conducted in Collaboration with Mayo Clinic Demonstrates 100% Sensitivity and Strong Predictive Power for Esophageal Cancer ...

Innovations like endoscopic imaging, AI-enhanced tools, and minimally invasive therapies are reshaping patient care. Despite challenges like public awareness gaps and cost barriers, strategic ...

Castle Biosciences (CSTL) announced new data demonstrating that its TissueCypher Barrett’s Esophagus test can provide risk insights beyond ...

Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee ...

FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that ...

An endoscopy—using a fiber‐optic tube to peer inside the body and collect biopsy samples—can be an invaluable way to detect ...

Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating PotentialUNIONDALE, NY, ...

Asset acquisition expected to expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders.

The American Gastroenterological Association (AGA) released a new clinical practice guideline on the surveillance of Barrett's esophagus, the only known precursor to esophageal cancer (adenocarcinoma) ...

The American Gastroenterological Association (AGA) today released a new clinical practice guideline on the surveillance of Barrett's esophagus, the only known precursor to esophageal cancer ...